Abbott beats estimates on medical devices demand as forecast hits shares

Abbott shares declined 8% after the company forecast third-quarter profit below Wall Street expectations ($1.28-$1.32 vs. $1.34) and narrowed its annual sales growth outlook, despite beating second-quarter revenue and adjusted EPS estimates. This negative guidance stems from an anticipated $200 million in annual tariff costs and a significant $700 million hit to its diagnostics segment due to declining COVID testing revenue and China's procurement program. While Abbott reported strong growth in continuous glucose monitoring devices and announced new U.S. manufacturing facilities, these positives were overshadowed by the substantial headwinds, disappointing investors given the stock's strong year-to-date performance.

Analysis

Abbott Laboratories (ABT) experienced a significant 8% share price decline following the release of a third-quarter profit forecast that fell short of analyst expectations, projecting between $1.28 and $1.32 per share against a consensus of $1.34. This negative outlook was compounded by a narrowing of its annual sales growth forecast to a 7.5% to 8.0% range and the disclosure of an anticipated $200 million annual cost from tariffs. Management specified these tariff impacts would be felt in the second half of the year. The guidance reflects two major headwinds: the aforementioned tariff costs and a substantial $700 million negative impact to its diagnostics segment, stemming from declining COVID-19 testing revenue and pricing pressure from China's bulk purchasing program. While the company delivered a marginal beat on second-quarter results, with revenue of $11.14 billion and adjusted EPS of $1.26 slightly ahead of estimates, these positives were overshadowed by the forward-looking challenges. A key bright spot remains the continuous glucose monitoring (CGM) business, which grew 21.4% to $1.9 billion. Abbott's long-term strategy to mitigate geopolitical risk includes new U.S. manufacturing facilities, but as an analyst noted, the stock's strong year-to-date performance set a high bar that this mixed report failed to clear.

Key Decisions for Investors

• Given the downward revisions to profit and sales guidance, investors should anticipate continued share price volatility and monitor the actual margin impact from tariffs in the second half of the year.
• The 8% share price decline may offer a more attractive entry point for long-term investors, contingent on the belief that the robust 21.4% growth in the CGM business can offset the medium-term headwinds in diagnostics, which management projects will subside by 2026.
• It is crucial to track the sales trajectory of the FreeStyle Libre franchise and the performance of the diagnostics unit in China, as these are the primary drivers of the bull and bear cases, respectively.